Halozyme Therapeutics is a biotechnology business based in the US. Halozyme Therapeutics shares (HALO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $61.19 – an increase of 1.02% over the previous week. Halozyme Therapeutics employs 350 staff and has a trailing 12-month revenue of around $1 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $61.19 |
|---|---|
| 52-week range | $40.19 - $66.00 |
| 50-day moving average | $60.74 |
| 200-day moving average | $56.19 |
| Wall St. target price | $68.13 |
| PE ratio | 17.8397 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $3.43 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $61.19 from 2025-05-02
| 1 week (2025-04-28) | 1.02% |
|---|---|
| 1 month (2025-04-04) | 2.38% |
| 3 months (2025-02-06) | 5.61% |
| 6 months (2024-11-06) | 0.92% |
| 1 year (2024-05-06) | 49.76% |
|---|---|
| 2 years (2023-05-05) | 97.39% |
| 3 years (2022-05-05) | 51.87% |
| 5 years (2020-05-05) | 156.35% |
Valuing Halozyme Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Halozyme Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Halozyme Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Halozyme Therapeutics shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Halozyme Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $627.1 million.
The EBITDA is a measure of a Halozyme Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1 billion |
|---|---|
| Operating margin TTM | 58.89% |
| Gross profit TTM | $776.9 million |
| Return on assets TTM | 18.16% |
| Return on equity TTM | 198.42% |
| Profit margin | 43.74% |
| Book value | $2.96 |
| Market Capitalization | $7.6 billion |
TTM: trailing 12 months
We're not expecting Halozyme Therapeutics to pay a dividend over the next 12 months.
Halozyme Therapeutics's shares were split on a 171:40 basis on 9 December 2003 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 171 shares. This wouldn't directly have changed the overall worth of your Halozyme Therapeutics shares – just the quantity. However, indirectly, the new 76.6% lower share price could have impacted the market appetite for Halozyme Therapeutics shares which in turn could have impacted Halozyme Therapeutics's share price.
Over the last 12 months, Halozyme Therapeutics's shares have ranged in value from as little as $40.185 up to $66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Halozyme Therapeutics's is 1.324. This would suggest that Halozyme Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Halozyme Therapeutics, Inc. , a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .